- Home
- GGR vs KYTX Comparison
GGR vs KYTX Comparison
Compare GGR & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGR
- KYTX
- Stock Information
- Founded
- GGR 2011
- KYTX 2018
- Country
- GGR Taiwan
- KYTX United States
- Employees
- GGR N/A
- KYTX N/A
- Industry
- GGR Auto Manufacturing
- KYTX
- Sector
- GGR Consumer Discretionary
- KYTX
- Exchange
- GGR Nasdaq
- KYTX NYSE
- Market Cap
- GGR 166.7M
- KYTX 196.4M
- IPO Year
- GGR N/A
- KYTX 2024
- Fundamental
- Price
- GGR $0.54
- KYTX $3.98
- Analyst Decision
- GGR Hold
- KYTX Buy
- Analyst Count
- GGR 2
- KYTX 5
- Target Price
- GGR $0.50
- KYTX $23.20
- AVG Volume (30 Days)
- GGR 765.6K
- KYTX 453.0K
- Earning Date
- GGR 02-05-2025
- KYTX 02-12-2025
- Dividend Yield
- GGR N/A
- KYTX N/A
- EPS Growth
- GGR N/A
- KYTX N/A
- EPS
- GGR N/A
- KYTX N/A
- Revenue
- GGR $329,041,000.00
- KYTX N/A
- Revenue This Year
- GGR N/A
- KYTX N/A
- Revenue Next Year
- GGR $3.73
- KYTX N/A
- P/E Ratio
- GGR N/A
- KYTX N/A
- Revenue Growth
- GGR N/A
- KYTX N/A
- 52 Week Low
- GGR $0.40
- KYTX $3.63
- 52 Week High
- GGR $2.67
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- GGR 44.28
- KYTX 38.40
- Support Level
- GGR $0.54
- KYTX $3.63
- Resistance Level
- GGR $0.65
- KYTX $4.60
- Average True Range (ATR)
- GGR 0.05
- KYTX 0.45
- MACD
- GGR -0.01
- KYTX -0.10
- Stochastic Oscillator
- GGR 2.08
- KYTX 8.58
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.